(MedPage Today) — The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), according to a meta-analysis…
Source link : https://www.medpagetoday.com/meetingcoverage/era/115988
Author :
Publish date : 2025-06-10 13:25:00
Copyright for syndicated content belongs to the linked Source.
